PNC-27 is a synthetic peptide based on residues from the human p53 protein linked to a membrane-penetrating motif. In preclinical research it binds HDM2 localiz…
Half-life
Not well characterized; expected short plasma stability typical of linear peptides (minutes to low hours) without specialized formulation
Delivery
Preclinical studies have explored intratumoral, perilesional, or topical/locoregional administration; systemic delivery remains investigational.
Suggested dosage
Not specified
Usage
Mechanism of action
Benefits (3)
- Potent cytotoxicity against HDM2-positive cancer cells in vitro
- Activity reported across multiple tumor cell lines in preclinical studies
- Mechanistically distinct from DNA-damaging chemotherapeutics
Side effects (3)
- Local irritation at administration site (preclinical)
- Potential off-target membrane toxicity/hemolysis at higher concentrations
- Unknown immunogenicity and systemic safety; not clinically approved